TargTex is a preclinical-stage biotech developing first-in-class TRPV2 modulators for oncology and cardiology, with multiple strategic paths open for value creation.

Our lead program, TTX101, is a nearly IND-ready locally delivered therapy for solid tumors, initially targeting glioblastoma, supported by a successful FDA pre-IND meeting and Orphan Drug Designation and a soft commitment from the EIC Accelerator for our current financing round.

In parallel, we are advancing next-generation TRPV2 inhibitors for cardiovascular diseases, with hypertrophic cardiomyopathy as the lead indication and recent in vivo findings strengthening TRPV2’s role in cardiac pathology.